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CAD is the main cause of death and disability worldwide and rep-
resents an archetypal common complex disease with both genetic 
and environmental determinants1,2. Thus far, 48 genomic loci have 
been found to harbor common SNPs in genome-wide significant 
association with the disease. Previous GWAS of CAD have tested the 
common disease–common variant hypothesis, with meta-analyses 
typically based on HapMap imputation training sets or tagging SNP 
arrays with up to 2.5 million SNPs (85% with MAF >0.05)3,4. The 
1000 Genomes Project5 has considerably expanded the coverage of 
human genetic variation, especially for lower-frequency variants 
and insertion-deletions (indels). We assembled 60,801 cases and 
123,504 controls from 48 studies for a GWAS meta-analysis of CAD; 
34,997 (57.5%) of the cases and 49,512 (40.1%) of the controls had been 
previously included in our Metabochip-based CAD meta-analysis 
(Supplementary Fig. 1) (ref. 3). Imputation was based on the 1000 
Genomes Project phase 1 v3 training set with 38 million variants, 
of which over half are low frequency (MAF < 0.005) and one-fifth 
are common (MAF > 0.05). The majority (77%) of the participants 
were of European ancestry; 13% and 6% were of South Asian (India 
and Pakistan) and East Asian (China and Korea) ancestry, respec-
tively, with smaller samples of Hispanic and African Americans 
(Supplementary Table 1). Case status was defined by an inclusive 
CAD diagnosis (for example, myocardial infarction, acute coronary 
syndrome, chronic stable angina or coronary stenosis of >50%). 
After selecting variants that met the allele frequency (MAF > 0.005) 
and imputation quality control criteria in at least 29 (>60%) of the 
studies, 8.6 million SNPs and 836,000 (9%) indels were included in 
the meta-analysis (Fig. 1); of these variants, 2.7 million (29%) were 
low frequency (0.005 < MAF < 0.05).
RESULTS
Scanning for additive associations
The results of an additive genetic model meta-analysis are 
summarized in Manhattan plots (Fig. 2 and Supplementary Fig. 2). 
Existing knowledge of genetic variants affecting risk of coronary artery disease (CAD) is largely based on genome-wide 
association study (GWAS) analysis of common SNPs. Leveraging phased haplotypes from the 000 Genomes Project, we report 
a GWAS meta-analysis of ~85,000 CAD cases and controls, interrogating 6.7 million common (minor allele frequency (MAF) > 
0.05) and 2.7 million low-frequency (0.005 < MAF < 0.05) variants. In addition to confirming most known CAD-associated loci, 
we identified ten new loci (eight additive and two recessive) that contain candidate casual genes newly implicating biological 
processes in vessel walls. We observed intralocus allelic heterogeneity but little evidence of low-frequency variants with larger 
effects and no evidence of synthetic association. Our analysis provides a comprehensive survey of the fine genetic architecture of 
CAD, showing that genetic susceptibility to this common disease is largely determined by common SNPs of small effect size.
In total, 2,213 variants (7.6% indels) showed significant associa-
tions (P < 5 × 10−8) with CAD with a low false discovery rate (FDR 
q value < 2.1 × 10−4). When these 2,213 variants were grouped into 
loci, 8 represented regions not previously reported as being associ-
ated with CAD at genome-wide levels of significance (Fig. 2 and 
Table 1). Of the 48 loci previously reported at genome-wide levels 
of significance, 47 showed nominally significant associations 
(Supplementary Table 2). The exception was rs6903956, the lead 
SNP for the ADTRP-C6orf105 locus detected in Han Chinese6, which 
previously showed no association in the Metabochip meta-analysis 
of Europeans and South Asians3. Thirty-six previously reported loci 
showed genome-wide significance (Supplementary Table 2). Monte 
Carlo simulations, guided by published effect sizes, suggest that our 
study was powered to detect 34 of the previously reported loci (95% 
confidence interval (CI) = 31–41 loci) at genome-wide significance. 
Hence, our findings are fully consistent with the previously identified 
CAD-associated loci.
The majority of the loci showing GWAS significance in the 
present analysis were well imputed (82% with imputation quality >0.9) 
(Fig. 3a) and had small effect sizes (odds ratio (OR) < 1.25) 
(Fig. 3b). An exception was the lead SNP in the newly associated 
chromosome 7q36.1 (NOS3) locus, rs3918226, which was only 
moderately well imputed (quality of 0.78), but the validity of this 
association was supported by existing genotype data, as rs3918226 
was present on the HumanCVD BeadChip for which data were 
available for some of the cohorts used in the present analysis, thereby 
allowing directly measured genotypes to be compared with imputed 
genotypes (Supplementary Table 3) (ref. 7). Three additional lower- 
frequency and moderately well-imputed SNPs in LPA and APOE 
(Fig. 3a), which were not previously reported in CAD GWAS3,4, also 
showed strong associations (LPA: rs10455872, P = 5.7 × 10−39 and 
rs3798220, P = 4.7 × 10−9; APOE: rs7412, P = 8.2 × 10−11). The LPA 
SNPs have previously been shown to be strongly associated with CAD 
in candidate gene studies based on experimental genotype data7,8. 
A comprehensive 1000 Genomes–based genome-wide 
association meta-analysis of coronary artery disease
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The minor allele of SNP rs7412 encodes the ε2 allele of APOE, and 
it has been well documented that carriers of the ε2 allele have lower 
cholesterol levels; significant protection from CAD by this allele 
was confirmed in a large meta-analysis9 and the Metabochip study 
(P = 0.0009) (ref. 3). However, rs7412 is not present on most com-
mercially available genome-wide genotyping arrays and cannot be 
imputed using HapMap reference panels, highlighting the value of 
the expanded coverage of the 1000 Genomes Project reference panels. 
Finally, SNP rs11591147 in PCSK9, which encodes the low-frequency 
(MAF = 0.01) p.Arg46Leu substitution that has been associated with 
low LDL (low-density lipoprotein) cholesterol levels and cardiopro-
tection10–13, was imperfectly imputed (imputation quality = 0.61). 
Nonetheless, these data provide the strongest evidence yet for a 
protective effect of this variant in CAD (P = 7.5 × 10−6).
Scanning for non-additive associations
Few GWAS of CAD have systematically scanned for associations 
that include dominance effects, and few truly recessive loci have 
been reported14,15. We used a recessive inheritance model to search 
for susceptibility effects conferred by homozygosity for the minor 
(less frequent) allele. Two new recessive susceptibility loci were iden-
tified with MAF = 0.09 and 0.36 and genotypic OR = 0.67 and 1.12, 
respectively (Fig. 2 and Table 1); these loci showed very little evidence 
of association under an additive model (Table 1). A supplementary 
analysis applying a dominant model identified multiple strong asso-
ciations with variants, all of which overlapped with loci identified in 
the analysis applying an additive model (Supplementary Table 4).
Myocardial infarction subphenotype analysis
Subgroup analysis in cases with a reported history of myocardial 
infarction (~70% of the total number of cases) did not identify any 
additional associations reaching genome-wide significance. The asso-
ciation results for the myocardial infarction subphenotype for the 48 
previously known CAD-associated loci and the 8 new additive CAD-
associated loci discovered in this study are shown in Supplementary 
Table 5. The odds ratios for the lead SNPs at 56 loci for the broader 
CAD phenotype (full cohort) and the myocardial infarction subpheno-
type are compared in Supplementary Figure 3. Although, as expected, 
the odds ratios were very similar for most of the loci, the odds ratios 
for the ABO and HDAC9 loci were sufficiently distinct in the two 
cohorts for their 95% confidence intervals to lie away from the line of 
equality, suggesting that the ABO locus preferentially associates with 
myocardial infarction and the HDAC9 locus preferentially associates 
with stable coronary disease but not myocardial infarction per se.
FDR and heritability analysis
We performed a joint association analysis to search for evidence of 
synthetic associations16, where multiple low-frequency susceptibility 
variants at a locus might be in LD with a common variant discov-
ered as the lead variant in a GWAS, and to compile an FDR-defined 
list of informative variants for annotation and heritability analysis3. 
Variants that showed suggestive additive association (P < 5 × 10−5) 
were assigned to 214 putative susceptibility loci of 2 cM centered 
on each lead variant, and all variants in these loci were examined; 
consequently, the search space for the joint analysis included 1,399,533 
variants. Using GCTA software17 to perform an approximate joint 
association analysis (Online Methods), we identified 202 FDR 
variants (q value < 0.05) in 129 loci (Supplementary Table 6) with 
multiple (2–14) tightly linked variants, corresponding to 57% of the 
putative CAD susceptibility loci. The 202 FDR variants were mostly 
common (median MAF = 0.22) and well imputed (median impu-
tation quality = 0.97). Ninety-five variants (explaining 13.3 ± 0.4%  
of CAD heritability) mapped to 44 significant loci from GWAS, and 93 
variants (explaining 12.9 ± 0.4% of CAD heritability) mapped to loci 
that included a previously reported significant variant from GWAS 
analysis. One hundred nine variants (explaining a further 9.3 ± 0.3% 
of CAD heritability) mapped to other loci. Fifteen low-frequency 
(MAF < 0.05) variants explained only 2.1 ± 0.2% of CAD heritability, 
indicating that our study was ~90% powered to detect OR >1.5 with 
low-frequency variants (Supplementary Table 7).
Common variants showing typical GWAS signals might be 
coupled with one or more low-frequency variants with relatively large 
effects16. We found no evidence for such synthetic associations in 
the joint association analysis; that is, all low-frequency variants were 
either a lead variant or were jointly associated (q value < 0.05) with 
a common variant. Twenty of the 202 FDR variants (9.9%) were 
indels (4–14 bp in size) as compared to 8.8% of all the variants in 
the meta-analysis (P = 0.60). Low-frequency variants (MAF < 0.05) 
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Figure 1 Comparing the 1000 Genomes Project and HapMap imputation 
training sets. Spectra of MAFs and median imputation quality (median 
info) scores showing the number (n) of variants in each bin. (a) The 
distribution for the 9.4 million 1000 Genomes Project phase 1 v3 
variants. (b) The distribution for 2.5 million HapMap 2 SNPs. Imputation 
quality was calculated as the median of the respective values in up to 48 
contributing studies; the imputation quality for genotyped variants was set 
equal to 1.0. The 1000 Genomes Project training set includes more low-
frequency variants, many of which have imputation qualities >0.9.
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were strikingly under-represented (6.9% ver-
sus 29.0%; P = 4.9 × 10−12), which may reflect 
on the statistical power to detect the modest 
effects associated with these variants.
Annotation and ENCODE analysis
Functional annotations were assigned to 
the 9.4 million variants studied in the CAD 
additive meta-analysis using ANNOVAR 
software18 (Supplementary Table 8). The 
202 FDR variants were depleted in intergenic 
regions (P = 2.5 × 10−7) and enriched in introns 
(P = 0.00035). Variants were also assigned 
to three sets of ENCODE (Encyclopedia of 
DNA Elements) features, namely histone/chromatin modifications 
(HMs), DNase I–hypersensitive sites (DHSs) and transcription factor 
binding sites (TFBSs) (Supplementary Table 9). The FDR variants 
showed independent enrichment across 11 cell types for the HM 
(P = 2.8 × 10−6) and DHS (P = 0.0003) ENCODE feature sets and 
with genic annotation status (P = 0.0013) (Supplementary Tables 10 
and 11). These associations were also evident in three cell types 
selected for maximal CAD relevance, with a 2.6-fold enrichment 
for DHSs, a 2.2-fold enrichment for HMs and a 1.6-fold enrichment 
for genic status (Supplementary Tables 12 and 13). These findings 
suggest that the 202 FDR variants are enriched for functional variants 
with potential relevance to CAD pathogenesis.
Post-hoc power calculations
Of the 9.4 million variants analyzed, 8.2 million (87%) were highly 
powered (>90%) to detect an OR ≥1.3 (Supplementary Table 7). The 
number of variants with power of ≥90% to detect associations varied 
systematically with allele frequency and imputation quality (results 
for OR = 1.3 shown in Supplementary Fig. 4); 1.5 million of the 
2.7 million (55%) low-frequency variants (0.005 < MAF < 0.05) in the 
meta-analysis were adequately powered to detect an OR ≥1.3, as most of 
these variants were accurately imputed (median imputation quality = 0.94, 
interquartile range = 0.88–0.98). Of the more common variants (MAF 
> 0.05), almost all (99.8%) were highly powered to detect an OR ≥1.3. 
However, in terms of total coverage of low-frequency variation, only 
15.3% of the 9.3 million low-frequency variants (0.005 < MAF < 0.05) 
in the 1000 Genomes Project phase 1 v3 training set met the 
 allele frequency and imputation quality entry criteria in the 60% of the 
studies required for inclusion in the meta-analysis and were predicted 
to be adequately powered to detect significant associations; 100% of 
these variants were highly powered (>90%) to detect an OR ≥3.15.
Interrogation of ten newly identified additive and recessive loci
We examined whether there were any expression quantitative trait loci 
(eQTLs), associations with known cardiovascular risk factors or prior 
evidence of the involvement of genes with atherosclerotic processes 
in each of the newly identified loci to define putative mechanisms by 
which the loci might affect risk of CAD.
At the chromosome 4q12 (REST-NOA1) locus, the lead SNP 
rs17087335 lies within an intron of the NOA1 gene (nitric oxide– 
associated 1); 23 SNPs in LD (r2 > 0.8) showed CAD associations 
(P < 1 × 10−6) across the NOA1 and REST (repressor element-1 
silencing transcription factor) genes (Fig. 4a). NOA1 encodes a 
GTP-binding protein involved in the regulation of mitochondrial 
respiration and apoptosis19. REST encodes a transcription factor that 
suppresses the expression of voltage-dependent sodium and potassium 
channels20; it has been shown to maintain vascular smooth muscle 
cells (VSMCs) in a quiescent, non-proliferative state and is itself 
downregulated in neointimal hyperplasia21. SNP rs17087335 showed 
a cis-eQTL signal for REST in lung22 (Supplementary Table 14).
At the chromosome 7q36.1 (NOS3) locus, the lead SNP rs3918226 
(MAF = 0.07) lies in the first intron of NOS3 (nitric oxide synthase 3) 
(Fig. 4b). This SNP was tentatively associated with CAD (OR = 1.14, 
P = 1.4 × 10−4) in a candidate gene meta-analysis based on 15,600 
Figure 2 A circular Manhattan plot  
summarizing the 1000 Genomes Project  
CAD association results. The meta-analysis 
statistics were adjusted for overdispersion 
(before applying double genomic control,  
λ = 1.18); overdispersion is predicted to be 
a regular feature in GWAS under a polygenic 
inheritance model60. The association statistics 
were capped at P = 1 × 10−20. Genome-wide 
significant variants (P < 5 × 10−8) are indicated 
by red triangles. New CAD-associated loci are 
indicated by red text (table 1). Previously 
reported loci showing genome-wide significant 
association are indicated by black text, and 
those showing nominal significance (P < 0.05) 
in our meta-analysis are indicated by blue 
text (supplementary table 2). The inner track 
shows the imputation quality scores of the 
lead variants in the new loci. The middle track 
shows numbered chromosome ideograms with 
centromeres represented by pink bars.
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cases and 35,000 controls genotyped with the HumanCVD BeadChip7 
and was firmly associated with essential hypertension (OR = 1.34, 
P = 1.0 × 10−14) (ref. 23). NOS3 is involved in the production of nitric 
oxide (NO), a potent vascular smooth muscle relaxant, and is a well-
studied candidate gene for CAD. Indeed, the genes encoding the com-
ponents of the NO receptor (soluble guanylyl cyclase) display both 
linkage and genome-wide association with CAD3,24. There are several 
overlapping ENCODE features in intron 1 of NOS3, suggesting a func-
tional role for rs3918226. However, there are 30 genes neighboring 
NOS3 within a 2-cM window centered on this variant, and the cur-
rent data do not allow the candidacy of these genes to be excluded. A 
nonsynonymous SNP, rs1799983, in NOS3 previously associated with 
cardiovascular phenotypes25 is in weak LD with rs3918226 but did not 
achieve significance in the additive or joint association analysis.
At the chromosome 11p15.4 (SWAP70) locus, SNP rs10840293 is 
intronic to SWAP70 (switch-associated protein-70) (Fig. 4c). SWAP-
70 is a signaling molecule involved in the regulation of filamentous 
actin networks26 in cell migration and adhesion. SNP rs10840293 and 
other SNPs in strong LD are cis eQTLs for SWAP70 in naive and chal-
lenged monocytes27, with SNP rs93138 showing strong association 
with CAD (P = 5.5 × 10−8) and being a cis eQTL for SWAP70 in naive 
and challenged monocytes28, fat29, skin29 and lung22 (Supplementary 
Table 14); three of the linked SNPs (rs93138, rs173396 and rs472109) 
are intronic and lie within ENCODE regulatory functional elements. 
Although this CAD-associated locus includes 33 genes, the eQTL 
and ENCODE data implicate SWAP70 as a plausible causal gene and 
suggest putative causal SNPs.
At the chromosome 15q22.33 (SMAD3) locus, the lead SNP 
rs56062135 is intronic to SMAD3 and the CAD association is tightly 
localized between two recombination hot spots (Fig. 4d). Mice lacking 
Smad3, a major downstream mediator of transforming growth 
factor (TGF)-β signaling, show enhanced neointimal hyperplasia 
with decreased matrix deposition in response to vascular injury30. 
SMAD3 was tentatively associated with CAD in an earlier GWAS31, 
although the lead SNP (rs17228212) in that association is in linkage 
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Figure 3 The imputation quality and effect size of lead variants at  
46 genome-wide significant loci. (a) The imputation quality and MAF  
for the lead variants at 46 genome-wide significant susceptibility loci. 
Blue circles, new additive loci; red squares, new recessive loci; black 
triangles, previously mapped additive loci; black diamonds, key SNPs  
in LPA and APOE. Imputation quality and MAF were each calculated as 
the median of the respective values in up to 48 contributing studies;  
the imputation quality for studies with genotype data was fixed at 1.0.  
(b) The odds ratio and effect allele frequency (EAF) for the lead variants  
at 46 genome-wide significant loci. Blue circles, new additive loci; red  
squares, new recessive loci; black triangles, previously mapped additive 
loci. SNPs rs55730499 and rs2891168 are lead variants in the LPA  
and chromosome 9p21 susceptibility loci, respectively. EAF was 
calculated as the median value in up to 48 contributing studies.
table 1 ten new cAD-associated loci
Lead variant Locus name Chr. A1/A2
Effect  
allele  
(A1)  
freq.
Imputation 
quality I 2
Heterogeneity 
P
n  
studiesa
Association model
Additive Recessive
OR (95% CI) P OR (95% CI) P
rs17087335 REST-NOA1 4 T/G 0.21 0.99 0.20 0.11 48 1.06 (1.04–1.09) 4.60 × 10−8 1.11 (1.05–1.17) 3.30 × 10−4
rs3918226 NOS3 7 T/C 0.06 0.78 0.15 0.19 45 1.14 (1.09–1.19) 1.70 × 10−9 1.26 (0.99–1.60) 5.96 × 10−2
rs10840293 SWAP70 11 A/G 0.55 0.94 0.17 0.16 47 1.06 (1.04–1.08) 1.30 × 10−8 1.05 (1.02–1.09) 1.51 × 10−3
rs56062135 SMAD3 15 C/T 0.79 0.98 0.00 0.67 46 1.07 (1.05–1.10) 4.50 × 10−9 1.17 (1.10–1.25) 8.88 × 10−7
rs8042271 MFGE8-ABHD2 15 G/A 0.9 0.93 0.16 0.19 46 1.10 (1.06–1.14) 3.70 × 10−8 1.25 (1.13–1.37) 7.27 × 10−6
rs7212798 BCAS3 17 C/T 0.15 0.95 0.14 0.21 48 1.08 (1.05–1.11) 1.90 × 10−8 1.17 (1.07–1.28) 6.12 × 10−4
rs663129 PMAIP1-MC4R 18 A/G 0.26 1.00 0.00 0.6 47 1.06 (1.04–1.08) 3.20 × 10−8 1.11 (1.06–1.17) 7.15 × 10−6
rs180803 POM121L9P-
ADORA2A
22 G/T 0.97 0.86 0.00 0.67 41 1.20 (1.13–1.27) 1.60 × 10−10 NA NA
rs11830157 KSR2 12 G/T 0.36 0.99 0.14 0.22 42 1.04 (1.02–1.06) 3.90 × 10−4 1.12 (1.08–1.16) 2.12 × 10−9
rs12976411 ZNF507-
LOC400684
19 T/A 0.09 0.93 0.50 5.09 × 10−4 34 0.95 (0.92–0.99) 9.10 × 10−3 0.67 (0.60–0.74) 1.18 × 10−14
Association results are presented for two inheritance models; results from the discovery association model are shown in bold. P values were adjusted for overdispersion  
following meta-analysis. Heterogeneity P values are for the respective discovery association model. Chr., chromosome; A1, effect allele; A2, non-effect allele; freq., frequency;  
I 2, heterogeneity inconsistency index; OR, odds ratio; CI, confidence interval; NA, not available owing to insufficient numbers (<60%) of studies having reliable results.
aThe number of studies that participated in the discovery result, where up to 48 studies participated in the additive model meta-analysis and up to 43 studies participated in the recessive  
model meta-analysis.
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equilibrium with rs56062135 and showed modest association 
(P = 0.009) in the present GWAS and no evidence of joint association 
(Supplementary Table 6).
At the chromosome 15q26.1 (MFGE8-ABHD2) locus, the lead 
intergenic SNP rs8042271 maps 117 kb upstream of MFGE8 (milk fat 
globule–EGF factor 8) and 57 kb upstream of ABHD2 (abhydrolase 
domain–containing protein 2) (Fig. 4e). MFGE8 (lactadherin) has a 
crucial role in vascular endothelial growth factor (VEGF)-dependent 
neovascularization32, and it is secreted from activated macrophages and 
binds to apoptotic cells, facilitating phagocytic engulfment33. ABHD2 
(ref. 34) has been shown to be expressed in human atherosclerotic lesions, 
with higher levels in patients with unstable angina. There were no over-
lapping risk factor quantitative trait locus (QTL), eQTL or ENCODE 
features in this locus to guide the nomination of a putative causal gene.
At the chromosome 17q23.2 (BCAS3) locus, the lead intronic SNP 
rs7212798 lies in BCAS3 (breast carcinoma amplified sequence 3) 
(Fig. 4f). Multiple variants in LD with rs7212798 map to BCAS3 
introns and showed strong association with CAD. BCAS3 encodes 
Figure 4 Regional association plots for newly identified loci associated with CAD. (a–h) Eight  
additive CAD loci. Plots are shown for the 4q12 (REST-NOA1) locus (a), the 7q36.1 (NOS3) 
locus (b), the 11p15.4 (SWAP70) locus (c), the 15q22.33 (SMAD3) locus (d), the 15q26.1 
(MFGE8-ABHD2) locus (e), the 17q23.2 (BCAS3) locus (f), the 18q21.32 (PMAIP1-MC4R) 
locus (g) and the 22q11.23 (POM121L9P-ADORA2A) locus (h). (i,j) Two recessive CAD loci. 
Plots are shown for the 12q24.23 (KSR2) locus (i) and the 19q13.11 (ZNF507-LOC400684) 
locus (j). The association statistics were adjusted for overdispersion following meta-analysis 
(genomic control parameter = 1.18 for the additive model and 1.05 for the recessive model). 
LD (r2) calculations were based on the combined 1000 Genomes Project phase 1 v3 training 
data set. Genomic coordinates refer to the hg19 sequence assembly.
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the Rudhira protein, which has been shown to activate Cdc42 to affect 
actin organization and control cell polarity and motility in endothelial 
cells, thus contributing to angiogenesis35.
At the chromosome 18q21.32 (PMAIP1-MC4R) locus, the lead 
intergenic SNP rs663129 lies 266 kb downstream of PMAIP1 (phorbol-
12-myristate-13-acetate–induced protein 1) and 200 kb downstream 
of MC4R (melanocortin 4 receptor) (Fig. 4g). PMAIP1 is a hypoxia-
inducible factor (HIF)-1α–induced proapoptotic gene that mediates 
hypoxic cell death by the generation of reactive oxygen species36. 
MC4R is a well-studied obesity-related locus, and the variant (and 
corresponding proxy variants) that were associated with higher CAD 
risk are also associated with body mass index (BMI) (P = 6 × 10−42) 
and obesity-associated risk factors, including higher triglyceride 
and lower high-density lipoprotein (HDL) concentrations and type 2 
diabetes37–41. However, we found no eQTL data or ENCODE features 
for the lead or proxy SNPs to further implicate MC4R as the causal 
gene underlying CAD susceptibility.
At the chromosome 22q11.23 (POM121L9P-ADORA2A) locus, the 
lead SNP rs180803 lies in POM121L9P (encoding the noncoding RNA 
POM121 transmembrane nucleoporin–like 9, pseudogene). A 2-cM 
region centered on this variant spans 1.2 Mb and includes 21 variants 
that were associated with CAD at genome-wide significance, most 
of which are in LD (r2 > 0.6) with the lead SNP and map to intronic 
regions of the SPECC1L and ADORA2A genes (Fig. 4h).
At the chromosome 12q24.23 (KSR2) locus, the lead SNP 
rs11830157 (MAF = 0.36) associated with CAD risk in a recessive 
model (genotypic OR = 1.12) is intronic to KSR2 (kinase suppressor of 
ras 2) (Fig. 4i) and overlaps with ENCODE functional elements. KSR2 
interacts with multiple proteins, including AMP-activated protein 
kinase (AMPK), and rare loss-of-function coding variants in KSR2 
are associated with severe obesity, hyperphagia and insulin resistance, 
a phenotype recapitulated in Ksr2-null mice42.
At the chromosome 19q13.11 (ZNF507-LOC400684) locus, the 
lead SNP rs12976411 (MAF = 0.09) lies in a gene for an unchar-
acterized noncoding RNA (LOC400684) and is 3.4 kb downstream 
of ZNF507 (Fig. 4j). The minor allele showed a protective effect in 
CAD (genotypic OR = 0.69) in the recessive model. ENCODE analysis 
of this locus suggests that several SNPs, including rs12981453 and 
rs71351160, which are in strong LD (r2 > 0.8) and are intronic to 
ZNF507, overlap with ENCODE functional elements.
DISCUSSION
We demonstrate that the ability of GWAS to investigate the genetic 
architecture of complex traits is enhanced by the 1000 Genomes 
Project. Analysis with this reference set has allowed us to conclude 
that low-frequency variants of larger effect, synthetic associations 
and indel polymorphisms are unlikely to explain a significant portion 
of the missing heritability for CAD. Rather, all ten newly identified 
CAD associations found in the present analysis, as well as all but one 
of the previously identified loci, are represented by risk alleles with 
a frequency of >5%. Thus, this comprehensive analysis strongly sup-
ports the common disease–common variant hypothesis43, given that 
it was powered to detect variants with MAF <0.05 having OR >1.5. 
Moreover, risk-associated alleles are significantly clustered within or 
close to genes and are enriched in regions with functional annota-
tions. Finally, genes implicated by this unbiased approach suggest 
hypotheses that explore the biology of the arterial vessel wall as a 
critical component of CAD pathogenesis.
The success of the GWAS meta-analysis strategy in mapping com-
mon, small-effect susceptibility variants for complex diseases has 
leaned heavily on genotype imputation with publically available 
training sets. The 1000 Genomes Project provides a substantial step-
up from the HapMap era in terms of coverage of lower-frequency 
variants and the integration of indel polymorphism (Fig. 1). The lead 
SNPs for four of the ten newly identified CAD loci were either absent 
or imperfectly tagged (r2 < 0.8) in the HapMap 2 training set, which 
reduced the power of discovering these loci in previous GWAS meta-
analyses. Although lower-frequency variants often show geographical 
differentiation5, the 1000 Genomes Project phase 1 v3 training set 
includes numerous low-MAF variants that are tractable to a global 
meta-analysis that includes ancestry groups from multiple continents. 
Key SNPs in APOE and PCSK9, which mediate their effects on CAD 
via LDL cholesterol–linked mechanisms, showed strong associations 
and reinforce the sensitivity of our 1000 Genomes Project analysis in 
detecting lower-frequency, imperfectly imputed susceptibility variants 
that were missed in HapMap-based GWAS.
Association analysis under the customary additive inheritance 
model widely used in GWAS is optimally powered to detect traits 
with no dominance variance but conveniently has adequate power 
to also detect dominantly inherited traits44. However, the additive 
model is systematically underpowered to detect recessively inherited 
traits, particularly with lower-frequency alleles44. This motivated our 
meta-analysis using a recessive model, which identified two new CAD 
risk loci, KSR2 and ZNF507-LOC400684, that escaped detection in a 
conventional additive association scan.
Our GWAS explores two potential sources of missing heritabil-
ity for CAD, as it includes indels and an extended panel of lower- 
frequency variants. Although there was no evidence that indels were 
systematically enriched for CAD association, they represented 10% 
of the 202 variants with an FDR q value <5%. In terms of survey-
ing the totality of human genetic variation, the 1.5 million of the 
2.7 million lower-frequency variants included in the meta-analysis with 
power to detect alleles of moderate penetrance (OR > 1.3) might seem 
modest. Yet the relative paucity of significant associations for these 
variants and the finding that 15 variants with MAF <0.05 explained 
2% of CAD heritability and provided no evidence of synthetic asso-
ciations will temper expectations for the role of low-frequency vari-
ants in CAD susceptibility, specifically with respect to risk prediction 
in a population-based setting. It is important to acknowledge that 
GWAS analysis based on SNP array data has limited power to resolve 
genes with rare mutation burdens. For example, LDLR45, APOA5  
(ref. 45), APOC3 (ref. 46) and NPC1L1 (ref. 47) are loaded with 
risk-conferring or protective mutations for CAD. These mutations 
were only discovered by whole-exome sequencing studies in large 
series of cases and controls and explain less than 1% of the missing 
heritability for CAD45.
Annotation analysis showed that the CAD-associated variants 
were significantly clustered within or close to genes. Furthermore, 
there was strong and independent enrichment for overlap of the 
CAD associations with ENCODE features, particularly in cell types 
relevant to CAD pathogenesis. This phenomenon has previously been 
reported for other diseases and traits48 and can guide candidate gene 
nomination and the design of future functional studies. We found few 
suggestions of overlap with risk factor QTLs or eQTLs in available 
data sets; this may in part reflect that the use of proxy variants can be 
limiting in cross-referencing the 1000 Genomes Project and HapMap 
association databases.
Coronary atherosclerosis underlies the development of the 
vast majority of myocardial infarction cases; therefore, the two 
are intimately related. However, additional factors, such as plaque 
vulnerability and the extent of the thrombotic reaction to plaque 
disruption, may predispose to myocardial infarction in the presence 
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of CAD49. We confirmed that ABO is particularly associated with 
risk of myocardial infarction50, suggesting that this locus may spe-
cifically increase the risk of plaque rupture and/or thrombosis. In 
contrast, HDAC9 showed a stronger association with CAD than 
with myocardial infarction, suggesting that it might predispose to 
atherosclerosis but not the precipitant events leading to a myocardial 
infarction. However, HDAC9 shows even stronger association with 
ischemic strokes involving thrombosis or embolism due to athero-
sclerosis of a large artery51. Although further epidemiological as well 
as experimental data are required to substantiate these findings, they 
suggest that certain loci may affect distinct mechanisms related to the 
development and progression of CAD.
Several of the genes implicated thus far in large-scale analyses 
of CAD susceptibility encode proteins with a known role in the 
biology of risk factors for CAD, notably circulating lipid levels and 
the metabolism of lipoproteins; other susceptibility genes are related 
to other known atherosclerosis risk factors, including genes impli-
cated in systemic inflammation and hypertension. Such findings are 
unsurprising, partly because of the undoubted importance of these 
known risk factors in the etiology of CAD but also because some 
of the previous analyses particularly targeted genes involved in risk 
factor traits; for example, HumanCVD BeadChip52 design was based 
on candidate genes, and the Metabochip studies3,53 drew on earlier 
association data with risk factor traits as well as an earlier HapMap 2–
based CAD GWAS meta-analysis54. The current experiment adopts a 
completely unbiased approach and, to our knowledge, is the first to do 
so at very large scale. In this respect, it is notable that, for some of the 
newly identified loci where genomic data, biological precedent and 
eQTL associations suggest a plausible candidate gene for CAD, the 
genes so implicated have well-documented roles in vessel wall biology. 
Their gene products are involved in diverse processes, including cell 
adhesion and leukocyte and VSMC migration (SWAP70 (ref. 26) and 
ABHD2 (ref. 55)), VSMC phenotypic switching (REST20), TGF-β  
signaling (SMAD3 (refs. 56,57)), anti-inflammatory and infarct- 
sparing effects (ADORA2A58 and MFGE8 (ref. 59)), angiogenesis 
(BCAS3 (ref. 35)) and NO signaling (NOS3 (ref. 24)).
It is important to note that these putative new susceptibility genes 
require substantial further investigation and validation before firm 
links to vascular biology can be established. A number of preventative 
strategies target the vessel wall (control of blood pressure and smok-
ing cessation), but the large majority of existing drug treatments for 
lowering CAD risk operate through manipulation of circulating lipid 
levels and few directly target vessel wall processes. Detailed investiga-
tion of new aspects of vessel wall biology that are implicated by genetic 
association but have not previously been explored in atherosclerosis 
may provide new insights into the complex etiology of disease and, 
hence, identify new targets.
URLs. Ensembl database, http://www.ensembl.org/; University of 
Chicago eQTL browser, http://eqtl.uchicago.edu/cgi-bin/gbrowse/
eqtl/; Genotype-Tissue Expression (GTEx) Portal, http://www.gtex-
portal.org/home/; Geuvadis Data Browser, http://www.ebi.ac.uk/
Tools/geuvadis-das/; CARDIoGRAMplusC4D Consortium, http://
www.cardiogramplusc4d.org/.
METhODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Association analysis. Three models of heritable disease susceptibility were 
analyzed by logistic regression: (i) an additive model where the log(genotype 
risk ratio) (log(GRR)) for a genotype was proportional to the number of risk 
alleles; (ii) a recessive model where the log(GRR) for homozygotes for the 
minor allele was compared with a reference risk in pooled heterozygotes 
and homozygotes for the major allele; and (iii) a dominant model where the 
log(GRR) for homozygotes for the minor allele pooled with heterozygotes 
was compared with a reference risk in homozygotes for the major allele. 
Minor and major alleles were identified by reference to allele frequencies in 
the pooled populations (all continents) of 1000 Genomes Project phase 1 v3 
data. For the recessive and dominant analyses, genotype probabilities were 
analyzed by all contributing studies to allow for variable imputation quality; 
for the additive analysis, genotype probabilities or allelic dosages were used 
(Supplementary Table 1).
Data quality control. Association data for each contributing study were indi-
vidually filtered for MAF >0.005 (estimated in cases and controls combined) 
and an imputation quality metric, rsq >0.3 for Minimac or info_proper >0.4 
for IMPUTE2 (ref. 61). Allele frequencies for each study were binned and 
compared with those from other studies to detect systematic flipping of alleles 
(Supplementary Fig. 5). Overdispersion of association statistics was assessed 
by the genomic control method62 (Supplementary Table 15), and adjusted 
values were submitted for meta-analysis. Variants that were retained in at least 
60% of the studies were submitted for meta-analysis using the GWAMA pro-
gram63. Following an inverse variance–weighted fixed-effects meta-analysis, 
heterogeneity was assessed by Cochran’s Q statistic64 and the I2 inconsistency 
index65, and variants showing marked heterogeneity were reanalyzed using a 
random-effects model66. Overdispersion in the resulting meta-analysis statis-
tics was adjusted for by a second application of the genomic control procedure 
(Supplementary Fig. 6).
FDR estimation. FDR was assessed using a step-up procedure coded in the 
qqvalue Stata program67. This procedure has been reported to be well control-
led under positive regression dependency conditions68; simulations based on 
1,000 permuted replicates of the PROCARDIS imputed data demonstrated 
that the FDR was conservatively controlled (theoretical q value = 0.05, empiri-
cal q value = 0.026, 95% CI = 0.017–0.038) in the context of the LD patterns 
prevalent in the 1000 Genomes Project phase 1 v3 training set.
GCTA and heritability analysis. Joint association analysis of the CAD additive 
meta-analysis results was performed using GCTA software17, which fits an 
approximate multiple regression model on the basis of summary association 
statistics and LD information derived from a reference genotype database 
(here the 1000 Genomes Project phase 1 v3 training set for all continents and 
populations that includes genotypes for 1,092 individuals). In this analysis, 
the lead variant is not necessarily retained in the final joint association model 
in situations where there might be multiple associated variants in strong LD. 
The accuracy of this analysis depends on appropriate ancestry matching as 
well as the sample size of the reference genotype panel to ensure that estimated 
LD correlations are unbiased and acceptably precise69. Simulations suggest 
that the expected correlation between P values based on the GCTA method 
using a reference panel of 1,000 genotyped samples and P values from ‘exact’ 
multiple regression based on experimental genotypes will be between 0.90 
and 0.95 (ref. 69). We investigated the empirical accuracy of the GCTA joint 
association analysis by comparing GCTA joint association results with those 
for a standard multiple–logistic regression analysis in four contributing 
studies (Supplementary Fig. 7). This comparison showed that 95% of the 
β values (regression coefficients) and standard errors were accurately approxi-
mated. The –log10 (P values) from the two analyses were positively correlated 
(0.86 < ρ < 0.93), with the GCTA method showing an insignificant trend 
(P > 0.20) toward yielding slightly inflated values.
Heritability calculations were based on a multifactorial liability-threshold 
model70 assuming that the disease prevalence was 5% and that the total herit-
ability of CAD was 40% (ref. 3); multiple regression estimates of allelic effect 
sizes were used following the GCTA joint association analysis. The standard 
errors for the heritability estimates were generated by Monte Carlo sampling 
with 1,000 replicates (for each variant, β values are drawn randomly from the 
variant’s β value ± s.e.m. estimate, heritability is calculated for each β value by 
replicate draw, heritability is summed across n variants within each replicate 
and, finally, the standard error of the heritability estimates is calculated across 
the 1,000 replicates).
Power calculations. Power to detect genetic associations depends on the 
magnitude of the genetic risk (effect size), the type I error rate, the risk 
allele frequency and imputation quality, and the sample size. Non-centrality 
parameter calculations were based on double–genomic controlled standard 
error estimates from the additive model meta-analysis; these estimates 
integrate information on allele frequency, imputation quality and sample size, 
which typically vary across studies. The type I error was set at 5 × 10−8, and an 
additive risk model was assumed.
Risk factor QTL survey. The ten newly identified CAD-associated loci 
were scanned for associations with heritable risk factors for CAD using 
publically available resources, including large-scale GWAS consortium data 
downloads37–41,71–73 and the National Human Genome Research Institute 
(NHGRI) GWAS catalog74 (accessed May 2014). As previous GWAS for risk 
factors were mainly based on HapMap 2–imputed data sets, all SNPs in LD 
(r2 > 0.8 based on the 1000 Genomes Project phase 1 v3 ALL reference panel) 
with the new variants were examined for risk factor associations. The newly 
associated loci were cross-referenced with known cis- and trans-eQTL asso-
ciations from the University of Chicago eQTL browser (accessed July 2014), 
the GTEx Portal (accessed June 2014), the Geuvadis Data Browser (accessed 
June 2014) and other published data22,28,29,75–79.
Annotation and ENCODE analysis. Variants were annotated using 
ANNOVAR software18 (version August 2013) based on a GRCh37/hg19 
gene annotation database. Upstream or downstream status was assigned to 
variants that mapped ≤1 kb from the transcript start or end, respectively. 
Variants without intergenic annotation were assigned a genic annotation 
status (42%). The annotation status of the 9.4 million variants included in the 
CAD additive meta-analysis is shown in Supplementary Table 8; 86% of the 
genic variants map to introns.
ENCODE features were downloaded from the Ensembl database using the 
Funcgen Perl API module (release 75). The list of ENCODE experiments stored 
in the Ensembl database can be browsed at http://Feb2014.archive.ensembl.
org/Homo_sapiens/Experiment/Sources?db=core;ex=project-ENCODE-. This 
list summarizes 100 different types of functional evidence in 11 different cell 
types for a total of 379 ENCODE experiments that identified 6,099,034 features. 
Variants that overlapped one or more of these features were cross-tabulated with 
their ANNOVAR annotation status (Supplementary Table 10); 50% of variants 
mapped to one or more ENCODE features, and variants in ENCODE features were 
strongly enriched for genic annotation status. Variants were grouped into three 
functional sets—HMs, DHSs and TFBSs (Supplementary Table 9). Cell types 
were grouped into CAD-relevant types and others (Supplementary Table 12) 
on the basis of their potential roles in CAD pathophysiology; hepatocytes (for 
example, lipid metabolism80), vascular endothelial cells (atherosclerosis81) 
and myoblasts (injury and repair82) were selected as being the most relevant 
to the CAD phenotype. Multiway contingency tables reporting ENCODE 
feature and ANNOVAR annotation status with inclusion in the list of vari-
ants with FDR <5% (FDR202 status) are summarized for 11 ENCODE cell 
types in Supplementary Table 11 and for the 3 CAD-relevant cell types in 
Supplementary Table 13. Contingency table counts were modeled by a logis-
tic multiple regression model predicting FDR202 status with the independent 
explanatory variables HM, DHS, TFBS and genic/intergenic status. The 
ENCODE83 project has previously mapped 4,492 significant GWAS SNPs from 
the NHGRI catalog74 (accessed June 2011) to transcription factor (12%) and 
DHS (34%) features in an extended data set of 1,640 experiments. The 202 
FDR variants were slightly less prevalent in these feature groups (10.4% trans-
cription factor and 19.8% DHS features), which could reflect a CAD-specific 
issue or a more general consequence of our analysis being based on a subset of 
the ENCODE data retrieved from the Ensembl database.
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